Nuclear heat shock protein 110 expression is associated with poor prognosis and hyperthermo-chemotherapy resistance in gastric cancer patients with peritoneal metastasis

Table 2 Univariate analyses of clinicopathological features affecting progression-free survival rates in patients after surgery

Clinicopathological variables	Univariate analysis
	RR	95%CI	P value
Age (< 65 yr/≥ 65 yr)	2.17	0.46-8.33	0.2988
Sex (male/female)	1.62	0.48-6.22	0.4412
Histology (differentiated/undifferentiated)	2.18	0.46-8.33	0.2988
Lymph node metastasis (absent/present)	1.25	0.19-5.02	0.7822
Lymphatic invasion (absent/present)	1.29	0.33-4.29	0.6904
Venous invasion (absent/present)	1.18	0.26-4.13	0.8057
Peritoneal lavage cytology (negative/positive)	1.32	0.38-6.10	0.6766
Peritoneal metastasis (absent/present)	2.28	0.58-15.08	0.2568
HSP110 expression (low/high)	3.40	0.94-16.01	0.0625

HSP110: Heat shock protein 110.